Chinese Chemical Letters, Journal Year: 2025, Volume and Issue: unknown, P. 110991 - 110991
Published: Feb. 1, 2025
Language: Английский
Bioorganic Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 108442 - 108442
Published: April 1, 2025
Language: Английский
Citations
1
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(9), P. 4832 - 4832
Published: April 29, 2024
This review offers a comprehensive exploration of the intricate immunological landscape breast cancer (BC), focusing on recent advances in diagnosis and prognosis through analysis circulating tumor cells (CTCs). Positioned within broader context BC research, it underscores pivotal role immune system shaping disease’s progression. The primary objective this investigation is to synthesize current knowledge aspects BC, with particular emphasis diagnostic prognostic potential offered by CTCs. adopts thorough examination relevant literature, incorporating breakthroughs field. methodology section succinctly outlines approach, specific focus CTC its implications for prognosis. Through review, insights into dynamic interplay between are highlighted, CTCs advancing methodologies refining assessments. Furthermore, presents substantiated results, contributing deeper understanding complexity BC. In conclusion, significance exploring profile patients, providing valuable novel utilization presentation findings emphasizes crucial dynamics, thereby opening avenues enhanced clinical management strategies.
Language: Английский
Citations
8
Current Drug Delivery, Journal Year: 2023, Volume and Issue: 21(7), P. 993 - 1009
Published: July 31, 2023
When breast cells divide and multiply out of control, it is called cancer. Symptoms include lump formation in the breast, a change texture or color discharge from nipple. Local systemic therapy frequently used to treat Surgical radiation procedures limited affected area are examples local management. There has been significant worldwide progress development monoclonal antibodies (mAbs) since 1986, when first therapeutic mAb, Orthoclone OKT3, became commercially available. mAbs can resist expansion cancer by inducing destruction cellular membranes, blocking immune system inhibitors, preventing new blood vessels. also target growth factor receptors. Understanding molecular pathways involved tumor its microenvironment crucial for developing effective targeted therapeutics. Due their unique properties, have wide range clinical applications. Antibody-drug conjugates (ADCs) drugs that improve index combining an antigen-specific antibody with payload. This review focuses on applications, mechanistic insights, characteristics, safety aspects, adverse events like trastuzumab, bevacizumab, pertuzumab, ertumaxomab, atezolizumab treatment. The creation novel technologies utilizing modified antibodies, such as fragments, conjugates, multi-specific must be central focus future studies. will help scientists working cancers more effectively.
Language: Английский
Citations
16
Trends in Pharmacological Sciences, Journal Year: 2024, Volume and Issue: 45(6), P. 552 - 576
Published: May 25, 2024
The epidermal growth factor receptor (EGFR) family is a class of transmembrane proteins, highly regarded as anticancer targets due to their pivotal role in various malignancies. Standard cancer treatments targeting the ErbB receptors include tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs). Despite substantial survival benefits, achievement curative outcomes hindered by acquired resistance. Recent advancements anti-ErbB approaches, such inhibitory peptides, nanobodies, targeted-protein degradation strategies, bispecific (BsAbs), aim overcome More recently, emerging insights into cell surface interactome open new avenues for modulating signaling specific domains partners. Here, we review recent progress elucidate paradigms that underscore significance EGF domain-containing proteins (EDCPs) ErbB-targeting pathways.
Language: Английский
Citations
5
Molecular and Clinical Oncology, Journal Year: 2024, Volume and Issue: 21(5)
Published: Aug. 20, 2024
Precision medicine in breast cancer is a revolutionary approach that customizes diagnosis and treatment based on individual tumor characteristics, departing from the traditional one-size-fits-all approach. Breast diverse, with various subtypes driven by distinct genetic mutations. Understanding this diversity crucial for tailored strategies target specific vulnerabilities each tumor. Genetic testing, particularly mutations gene (BRCA) DNA repair-associated genes, helps assess hereditary risks influences decisions. Molecular subtyping guides personalized treatments, such as hormonal therapies receptor-positive tumors human epidermal growth factor receptor 2 (HER2)-targeted treatments. Targeted therapies, including those HER2-positive hormone cancers, offer more effective precise interventions. Immunotherapy, especially checkpoint inhibitors, shows promise, certain triple-negative cancer, ongoing research aiming to broaden its effectiveness. Integration of big data artificial intelligence enhances strategies, while liquid biopsies provide real-time insights into dynamics, aiding monitoring modification. Challenges persist, accessibility complexity, but emerging technologies precision prevention hope improved outcomes. Ultimately, aims optimize efficacy, minimize adverse effects enhance quality life patients cancer.
Language: Английский
Citations
5
Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13
Published: Nov. 9, 2023
Triple-negative breast cancers (TNBCs) are more likely to occur in younger patients and have a poor prognosis. They highly heterogeneous tumors consisting of different molecular subtypes. The only common characteristic among them is the absence targets for endocrine therapy human epidermal growth factor receptor 2 (HER2) blockade. In past two decades, there has been an increased understanding these from perspective, leading their stratification according new therapeutic strategies. TNBC ushered carcinomas into era immunotherapy. higher frequency germline BRCA mutations enables targeting this repair defect by drugs like PARP inhibitors, resulting synthetic lethality neoplastic cells. Additionally, we identification molecules which generation smart drugs, such as antibody-drug conjugates (ADCs), directed. review, will discuss trajectory knowledge systematic manner, presenting bases, possibilities, biomarkers.
Language: Английский
Citations
13
Journal of Robotic Surgery, Journal Year: 2024, Volume and Issue: 18(1)
Published: Feb. 24, 2024
Language: Английский
Citations
4
Neoplasia, Journal Year: 2024, Volume and Issue: 56, P. 101024 - 101024
Published: July 23, 2024
Cancer poses a major threat to human health worldwide. The development of anti-tumor materials provides new modalities for cancer diagnosis and treatment. In this review, we comprehensively summarize the research progress clinical applications materials. First, introduce etiology pathogenesis cancer, significance challenges research. Then, classify discuss their mechanisms action. After that, elaborate advances materials, including those targeting tumor cells therapeutic instruments. Finally, future perspectives in field This review aims provide an overview current status application, offer insights into directions rapidly evolving field, which holds promise more precise, efficient customized treatment cancer.
Language: Английский
Citations
4
Current Plant Biology, Journal Year: 2025, Volume and Issue: 42, P. 100435 - 100435
Published: Jan. 7, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(3), P. 1079 - 1079
Published: Jan. 26, 2025
Monoclonal antibody (mAb) and cell-based immunotherapies represent cutting-edge strategies for cancer treatment. However, safety concerns persist due to the potential targeting of normal cells that express reactive antigens. Therefore, it is crucial develop cancer-specific mAbs (CasMabs) can bind antigens exhibit antitumor activity in vivo, thereby reducing risk adverse effects. We previously screened human epidermal growth factor receptor 2 (HER2) successfully developed a anti-HER2 mAb, H2Mab-250/H2CasMab-2 (mouse IgG1, kappa). In this study, we assessed both vitro vivo efficacy humanized H2Mab-250 (humH2Mab-250). Although humH2Mab-250 showed lower reactivity HER2-overexpressed Chinese hamster ovary-K1 (CHO/HER2) breast cell lines (BT-474 SK-BR-3) than trastuzumab flow cytometry, similar antibody-dependent cellular cytotoxicity (ADCC) against CHO/HER2 presence effector splenocytes. addition, exhibited significant complement-dependent (CDC) compared trastuzumab. Furthermore, possesses compatible effects xenografts with These findings highlight distinct roles ADCC CDC suggest direction clinical development HER2-positive tumors.
Language: Английский
Citations
0